Furthermore, our TIMER database analysis revealed that ZDHHC20 expression levels were higher in tumor tissues from pancreatic cancer patients harboring KRAS mutations than in those without KRAS mutation (Fig. 2B). Here, KRAS is linked to pancreatic neoplasm.